Alobresib
CAS No. : 1637771-14-2
(Synonyms: GS-5829)
| Size | Price | Stock |
|---|---|---|
| 1mg | $85 | In-stock |
| 5mg | $160 | In-stock |
| 10mg | $220 | In-stock |
| 25mg | $435 | In-stock |
| 50mg | $695 | In-stock |
| 100mg | $1110 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-109050 |
| M.Wt: | 437.49 |
| Formula: | C26H23N5O2 |
| Purity: | >98 % |
| Solubility: | DMSO : 83.33 mg/mL (ultrasonic) |
Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research[1][2].
IC50 & Target:BET bromodomain[1]
In Vitro:Alobresib (0.1 nM-100 μM; 72 hours) inhibits cell proliferation in primary uterine serous carcinoma (USC) lines[1].
In Vivo:Alobresib (10 and 20 mg/kg; oral; twice-daily; for 28 days) impaires USC-ARK2 xenograft tumor growth in female CB17/lcrHsd-Prkd/scid mice. Alobresib exhibits a significantly slower rate of tumor growth in mice, compared with vehicle control and to mice undergoing daily treatment with JQ1 (50 mg/kg/day i.p.)[1].
Alobresib (10 and 20 mg/kg; oral; twice-daily; for 28 days) is well tolerated with no clear impact on body weight compared with vehicle control[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Alobresib
- Cat. No.:
- HY-109050
- Quantity:
Your information is safe with us.